Bromelains (Wobenzym N Tablets)â must not be used in case of known hypersensitivity to its active or inactive ingredients. The preparation must not be used by patients with severe inborn or gained coagulation disorders (e.g. hemophilia, severe liver damage, dialyzed patients). Administration of Bromelains (Wobenzym N Tablets)® during pregnancy and breastfeeding should be consulted with a physician. This applies also when getting pregnant during the treatment.
See also:
What is the most important information I should know about Pancreatin (Wobenzym N Tablets)?
Hypersensitivity to Pancreatin (Wobenzym N Tablets) or to any of the excipients of Pancreatin (Wobenzym N Tablets).
Patients w/ generalised or systemic infections or w/ disorders of blood coagulation.
Bromelains (Wobenzym N Tablets) may cause nausea, vomiting, and diarrhoea. Metrorrhagia and menorrhagia have occasionally occurred. Hypersensitivity reactions have been reported and have included skin reactions and asthma.
See also:
What are the possible side effects of Pancreatin (Wobenzym N Tablets)?
The most serious adverse reactions reported with different pancreatic enzyme products of the same active ingredient (pancrelipase) that are described elsewhere in the label include fibrosing colonopathy, hyperuricemia and allergic reactions.
Clinical Trials ExperienceBecause clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The short-term safety of Pancreatin (Wobenzym N Tablets) was assessed in clinical trials conducted in 121 patients with exocrine pancreatic insufficiency (EPI): 67 patients with EPI due to cystic fibrosis (CF) and 25 patients with EPI due to chronic pancreatitis or pancreatectomy were treated with Pancreatin (Wobenzym N Tablets).
Cystic FibrosisStudies 1 and 2 were randomized, double-blind, placebo-controlled, crossover studies of 49 patients, ages 7 to 43 years, with EPI due to CF. Study 1 included 32 patients ages 12 to 43 years and Study 2 included 17 patients ages 7 to 11 years. In these studies, patients were randomized to receive Pancreatin (Wobenzym N Tablets) at a dose of 4,000 lipase units/g fat ingested per day or matching placebo for 5 to 6 days of treatment, followed by crossover to the alternate treatment for an additional 5 to 6 days. The mean exposure to Pancreatin (Wobenzym N Tablets) during these studies was 5 days.
In Study 1, one patient experienced duodenitis and gastritis of moderate severity 16 days after completing treatment with Pancreatin (Wobenzym N Tablets). Transient neutropenia without clinical sequelae was observed as an abnormal laboratory finding in one patient receiving Pancreatin (Wobenzym N Tablets) and a macrolide antibiotic.
In Study 2, adverse reactions that occurred in at least 2 patients (greater than or equal to 12%) treated with Pancreatin (Wobenzym N Tablets) were vomiting and headache. Vomiting occurred in 2 patients treated with Pancreatin (Wobenzym N Tablets) and did not occur in patients treated with placebo; headache occurred in 2 patients treated with Pancreatin (Wobenzym N Tablets) and did not occur in patients treated with placebo.
The most common adverse reactions (greater than or equal to 4%) in Studies 1 and 2 were vomiting, dizziness, and cough. Table 1 enumerates adverse reactions that occurred in at least 2 patients (greater than or equal to 4%) treated with Pancreatin (Wobenzym N Tablets) at a higher rate than with placebo in Studies 1 and 2.
Table 1: Adverse Reactions Occurring in at Least 2 Patients (greater than or equal to 4%) in Cystic Fibrosis (Studies 1 and 2)
| Adverse Reaction | Pancreatin (Wobenzym N Tablets) Capsules n = 49(%) | Placebo n = 47(%) |
| Vomiting | 3 (6) | 1 (2) |
| Dizziness | 2 (4) | 1 (2) |
| Cough | 2 (4) | 0 |
An additional open-label, single-arm study assessed the short-term safety and tolerability of Pancreatin (Wobenzym N Tablets) in 18 infants and children, ages 4 months to 6 years, with EPI due to cystic fibrosis. Patients received their usual pancreatic enzyme replacement therapy (mean dose of 7,000 lipase units/kg/day for a mean duration of 18.2 days) followed by Pancreatin (Wobenzym N Tablets) (mean dose of 7,500 lipase units/kg/day for a mean duration of 12.6 days). There were no serious adverse reactions. Adverse reactions that occurred in patients during treatment with Pancreatin (Wobenzym N Tablets) were vomiting, irritability, and decreased appetite, each occurring in 6% of patients.
Chronic Pancreatitis or PancreatectomyA randomized, double-blind, placebo-controlled, parallel group study was conducted in 54 adult patients, ages 32 to 75 years, with EPI due to chronic pancreatitis or pancreatectomy. Patients received single-blind placebo treatment during a 5-day run-in period followed by an intervening period of up to 16 days of investigatordirected treatment with no restrictions on pancreatic enzyme replacement therapy. Patients were then randomized to receive Pancreatin (Wobenzym N Tablets) or matching placebo for 7 days. The Pancreatin (Wobenzym N Tablets) dose was 72,000 lipase units per main meal (3 main meals) and 36,000 lipase units per snack (2 snacks). The mean exposure to Pancreatin (Wobenzym N Tablets) during this study was 6.8 days in the 25 patients that received Pancreatin (Wobenzym N Tablets).
The most common adverse reactions reported during the study were related to glycemic control and were reported more commonly during Pancreatin (Wobenzym N Tablets) treatment than during placebo treatment.
Table 2 enumerates adverse reactions that occurred in at least 1 patient (greater than or equal to 4%) treated with Pancreatin (Wobenzym N Tablets) at a higher rate than with placebo.
Table 2: Adverse Reactions in at Least 1 Patient (greater than or equal to 4%) in the Chronic Pancreatitis or Pancreatectomy Trial
| Adverse Reaction | Pancreatin (Wobenzym N Tablets) Capsules n = 25(%) | Placebo n = 29 (%) |
| Hyperglycemia | 2 (8) | 2 (7) |
| Hypoglycemia | 1 (4) | 1 (3) |
| Abdominal Pain | 1 (4) | 1 (3) |
| Abnormal Feces | 1 (4) | 0 |
| Flatulence | 1 (4) | 0 |
| Frequent Bowel Movements | 1 (4) | 0 |
| Nasopharyngitis | 1 (4) | 0 |
Postmarketing data from this formulation of Pancreatin (Wobenzym N Tablets) have been available since 2009. The following adverse reactions have been identified during post approval use of this formulation of Pancreatin (Wobenzym N Tablets). Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Gastrointestinal disorders (including abdominal pain, diarrhea, flatulence, constipation and nausea), skin disorders (including pruritus, urticaria and rash), blurred vision, myalgia, muscle spasm, and asymptomatic elevations of liver enzymes have been reported with this formulation of Pancreatin (Wobenzym N Tablets).
Delayed- and immediate-release pancreatic enzyme products with different formulations of the same active ingredient (pancrelipase) have been used for the treatment of patients with exocrine pancreatic insufficiency due to cystic fibrosis and other conditions, such as chronic pancreatitis. The long-term safety profile of these products has been described in the medical literature. The most serious adverse reactions included fibrosing colonopathy, distal intestinal obstruction syndrome (DIOS), recurrence of pre-existing carcinoma, and severe allergic reactions including anaphylaxis, asthma, hives, and pruritus.
Hypersensitivity reactions have occurred.
Effects on the eyes.
Ocular and periorbital angioedema occurring within 4 hours of use of a contact lens cleansing solution containing Papain (Wobenzym N Tablets) has been reported.1
Extensive destruction of the oesophageal wall, with perforation, resulted from the use of a Papain (Wobenzym N Tablets) suspension given to treat an obstruction caused by impacted meat.1 The patient had been given 1.2 g of Papain (Wobenzym N Tablets) over a 12-hour period. Ten days after a thoracotomy, the descending thoracic aorta ruptured, and she died from haemorrhage.
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Less serious side effects are more likely to occur, and you may have none at all.
Tell your doctor, pharmacist, herbalist, or other healthcare provider about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.
Bromelains (Wobenzym N Tablets) have been given as an aid to digestion,Bromelains (Wobenzym N Tablets) are a concentrate of proteolytic enzymes derived from the pineapple plant, Ananas comosus (A. sativus) (Bromeliaceae).
An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.Pancreatic insufficiency
Pancreatic enzyme supplements commonly cause gastrointestinal adverse effects such as abdominal discomfort and nausea and vomiting. They may also cause buccal and perianal irritation, particularly in infants. Colonic strictures (fibrosing colonopathy) have occurred, mainly in children with cystic fibrosis receiving high doses of Pancreatin (Wobenzym N Tablets) preparations; the use of high doses in patients with cystic fibrosis should preferably be avoided. Adequate hydration should be maintained at all times in patients receiving higher strength preparations.
An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.Papain (Wobenzym N Tablets) consists chiefly of a mixture of Papain (Wobenzym N Tablets) and chymopapain, proteolytic enzymes that hydrolyse polypeptides, amides, and esters, especially at bonds involving basic amino acids, or leucine or glycine, yielding peptides of lower molecular weight. It is used with urea as a topical debriding agent. It is also used for the removal of protein deposits from the surface of soft contact lenses ().
Preparations of Papain (Wobenzym N Tablets), alone or combined with antibacterial agents and/or other substances, have been taken by mouth for their supposed anti-inflammatory properties, and it has also been used as an ingredient of various mixtures claimed to aid digestion.
Papain (Wobenzym N Tablets) is widely used as a meat tenderiser and in the clarification of beverages.
Malignant neoplasms.
Papain (Wobenzym N Tablets) has been included in proteolytic enzyme preparations used in oncology to reduce the adverse effects of chemotherapy and radiotherapy. Although the number of clinical studies on which to judge efficacy is limited, a review1 of such studies suggested that systemic enzyme therapy might be beneficial. Clinical studies have used a preparation containing Papain (Wobenzym N Tablets), trypsin, and chymotrypsin in a weight ratio of 5:2:2, and the beneficial effect seems to be based on its anti-inflammatory potential.
An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.peripheral vascular disorders
Pancreatin (Wobenzym N Tablets) (pancrelipase) is a combination of three enzymes (proteins): lipase, protease, and amylase. These enzymes are normally produced by the pancreas and are important in the digestion of fats, proteins, and sugars.
Pancreatin (Wobenzym N Tablets) is used to replace these enzymes when the body does not have enough of its own. Certain medical conditions can cause this lack of enzymes, including cystic fibrosis, chronic inflammation of the pancreas, or blockage of the pancreatic ducts.
Pancreatin (Wobenzym N Tablets) may also be used following surgical removal of the pancreas.
Pancreatin (Wobenzym N Tablets) may also be used for purposes not listed in this medication guide.
Bioflavonoids are found in the rind of green citrus fruits and in rose hips and black currants.
Bioflavonoids have been used in alternative medicine as an aid to enhance the action of vitamin C, to support blood circulation, as an antioxidant, and to treat allergies, viruses, or arthritis and other inflammatory conditions.
Not all uses for bioflavonoids have been approved by the FDA. Bioflavonoids should not be used in place of medication prescribed for you by your doctor.
Bioflavonoids is often sold as an herbal supplement. There are no regulated manufacturing standards in place for many herbal compounds and some marketed supplements have been found to be contaminated with toxic metals or other drugs. Herbal/health supplements should be purchased from a reliable source to minimize the risk of contamination.
Bioflavonoids may also be used for other purposes not listed in this product guide.
Not all uses for bioflavonoids have been approved by the FDA. Bioflavonoids should not be used in place of medication prescribed for you by your doctor.
Bioflavonoids is often sold as an herbal supplement. There are no regulated manufacturing standards in place for many herbal compounds and some marketed supplements have been found to be contaminated with toxic metals or other drugs. Herbal/health supplements should be purchased from a reliable source to minimize the risk of contamination.
Use bioflavonoids as directed on the label, or as your healthcare provider has prescribed. Do not use this product in larger amounts or for longer than recommended.
Each hard-gelatin capsule contains Pancreatin (Wobenzym N Tablets) (pancreas powder) 150 mg corresponding to amylase 8000 Ph Eur units, lipase 10,000 Ph Eur units and protease 600 Ph Eur units. It also contains the following excipients: Core Pellet: Macrogol 4000. Pellet Coating: Hypermellose phthalate, dimethicone 1000, triethyl citrate, cetyl alcohol. Capsule: Iron oxide (E172), titanium dioxide (E171), sodium lauryl sulphate, gelatin.
Use Pancreatin (Wobenzym N Tablets) as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Pancreatin (Wobenzym N Tablets).
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.This medication contains digestive enzymes, which are natural substances needed by the body to help break down and digest food. It is used when the pancreas cannot make or does not release enough digestive enzymes into the gut to digest the food. Depending on the amount of enzymes in your product, it may be used for indigestion, as a supplement, or as replacement therapy (e.g., in chronic pancreatitis, cystic fibrosis, cancer of the pancreas, after surgery on the pancreas or gut).
Some supplement products have been found to contain possibly harmful impurities/additives. Check with your pharmacist for more details about the brand you use.
The FDA has not reviewed this product for safety or effectiveness. Consult your doctor or pharmacist for more details.
How to use Pancreatin (Wobenzym N Tablets) 4XTake this medication by mouth with meals and snacks as directed by your doctor.
The dosage is based on your medical condition, diet, and response to treatment.
If you are using the tablet form of the medication, make sure not to keep it in the mouth because doing so can cause irritation to the gums and cheeks. Swallow the medication with water. For the chewable tablets, chew thoroughly before swallowing.
If you are using the capsule form of the medication and swallowing is difficult, the capsule may be opened and the powder mixed with food or liquid.
Be careful not to inhale any of the powder because doing so can irritate the inside of the nose or cause an asthma attack.
Use this medication regularly to get the most benefit from it.
If your doctor has recommended that you follow a special diet, it is very important to follow the diet to get the most benefit from this medication.
Do not change brands or dosage forms of this product without consulting your doctor or pharmacist. Different products may contain different amounts of the digestive enzymes.
Tell your doctor if your condition persists or worsens.
Pancreatin (Wobenzym N Tablets) is not interchangeable with other pancrelipase products.
Pancreatin (Wobenzym N Tablets) is orally administered. Therapy should be initiated at the lowest recommended dose and gradually increased. The dosage of Pancreatin (Wobenzym N Tablets) should be individualized based on clinical symptoms, the degree of steatorrhea present, and the fat content of the diet as described in the Limitations on Dosing below.
AdministrationInfants (up to 12 months)Pancreatin (Wobenzym N Tablets) should be administered to infants immediately prior to each feeding, using a dosage of 3,000 lipase units per 120 mL of formula or prior to breast-feeding. Contents of the capsule may be administered directly to the mouth or with a small amount of applesauce. Administration should be followed by breast milk or formula. Contents of the capsule should not be mixed directly into formula or breast milk as this may diminish efficacy. Care should be taken to ensure that Pancreatin (Wobenzym N Tablets) is not crushed or chewed or retained in the mouth, to avoid irritation of the oral mucosa.
Children and AdultsPancreatin (Wobenzym N Tablets) should be taken during meals or snacks, with sufficient fluid. Pancreatin (Wobenzym N Tablets) capsules and capsule contents should not be crushed or chewed. Capsules should be swallowed whole.
For patients who are unable to swallow intact capsules, the capsules may be carefully opened and the contents added to a small amount of acidic soft food with a pH of 4.5 or less, such as applesauce, at room temperature. The Pancreatin (Wobenzym N Tablets)-soft food mixture should be swallowed immediately without crushing or chewing, and followed with water or juice to ensure complete ingestion. Care should be taken to ensure that no drug is retained in the mouth.
DosageDosage recommendations for pancreatic enzyme replacement therapy were published following the Cystic Fibrosis Foundation Consensus Conferences.1, 2, 3 Pancreatin (Wobenzym N Tablets) should be administered in a manner consistent with the recommendations of the Cystic Fibrosis Foundation Consensus Conferences (also known as Conferences) provided in the following paragraphs, except for infants. Although the Conferences recommend doses of 2,000 to 4,000 lipase units in infants up to 12 months, Pancreatin (Wobenzym N Tablets) is available in a 3,000 lipase unit capsule. Therefore, the recommended dose of Pancreatin (Wobenzym N Tablets) in infants up to 12 months is 3,000 lipase units per 120 mL of formula or per breast-feeding. Patients may be dosed on a fat ingestion-based or actual body weight-based dosing scheme.
Additional recommendations for pancreatic enzyme therapy in patients with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy are based on a clinical trial conducted in these populations.
Infants (up to 12 months)Pancreatin (Wobenzym N Tablets) is available in the strength of 3,000 USP units of lipase thus infants may be given 3,000 lipase units (one capsule) per 120 mL of formula or per breast-feeding. Do not mix Pancreatin (Wobenzym N Tablets) capsule contents directly into formula or breast milk prior to administration.
Children Older than 12 Months and Younger than 4 YearsEnzyme dosing should begin with 1,000 lipase units/kg of body weight per meal for children less than age 4 years to a maximum of 2,500 lipase units/kg of body weight per meal (or less than or equal to 10,000 lipase units/kg of body weight per day), or less than 4,000 lipase units/g fat ingested per day.
Children 4 Years and Older and AdultsEnzyme dosing should begin with 500 lipase units/kg of body weight per meal for those older than age 4 years to a maximum of 2,500 lipase units/kg of body weight per meal (or less than or equal to 10,000 lipase units/kg of body weight per day), or less than 4,000 lipase units/g fat ingested per day.
Usually, half of the prescribed Pancreatin (Wobenzym N Tablets) dose for an individualized full meal should be given with each snack. The total daily dose should reflect approximately three meals plus two or three snacks per day.
Enzyme doses expressed as lipase units/kg of body weight per meal should be decreased in older patients because they weigh more but tend to ingest less fat per kilogram of body weight.
Adults with Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis or PancreatectomyThe initial starting dose and increases in the dose per meal should be individualized based on clinical symptoms, the degree of steatorrhea present, and the fat content of the diet.
In one clinical trial, patients received Pancreatin (Wobenzym N Tablets) at a dose of 72,000 lipase units per meal while consuming at least 100 g of fat per day. Lower starting doses recommended in the literature are consistent with the 500 lipase units/kg of body weight per meal lowest starting dose recommended for adults in the Cystic Fibrosis Foundation Consensus Conferences Guidelines. If symptoms and signs of steatorrhea persist, the dosage may be increased by the healthcare professional. Patients should be instructed not to increase the dosage on their own. There is great inter-individual variation in response to enzymes; thus, a range of doses is recommended. Changes in dosage may require an adjustment period of several days. If doses are to exceed 2,500 lipase units/kg of body weight per meal, further investigation is warranted. Doses greater than 2,500 lipase units/kg of body weight per meal (or greater than 10,000 lipase units/kg of body weight per day) should be used with caution and only if they are documented to be effective by 3-day fecal fat measures that indicate a significantly improved coefficient of fat absorption. Doses greater than 6,000 lipase units/kg of body weight per meal have been associated with colonic stricture, indicative of fibrosing colonopathy, in children less than 12 years of age. Patients currently receiving higher doses than 6,000 lipase units/kg of body weight per meal should be examined and the dosage either immediately decreased or titrated downward to a lower range.
How suppliedDosage Forms And StrengthsThe active ingredient in Pancreatin (Wobenzym N Tablets) evaluated in clinical trials is lipase. Pancreatin (Wobenzym N Tablets) is dosed by lipase units.
Other active ingredients include protease and amylase. Each Pancreatin (Wobenzym N Tablets) delayed-release capsule strength contains the specified amounts of lipase, protease, and amylase as follows:
3,000 USP units of lipase; 9,500 USP units of protease; 15,000 USP units of amylase
Each Pancreatin (Wobenzym N Tablets) capsule is available as a two piece hypromellose capsule with a white opaque cap with imprint “Pancreatin (Wobenzym N Tablets) 1203” and a white opaque body that contains tan colored, delayed-release pancrelipase supplied in bottles of:
70 capsules (NDC 0032-1203-70)
Pancreatin (Wobenzym N Tablets) (pancrelipase) Delayed-Release Capsules6,000 USP units of lipase; 19,000 USP units of protease; 30,000 USP units of amylase
Each Pancreatin (Wobenzym N Tablets) capsule is available as a two-piece gelatin capsule with orange opaque cap with imprint “Pancreatin (Wobenzym N Tablets) 1206” and a blue opaque body that contains tan-colored, delayed-release pancrelipase supplied in bottles of:
100 capsules (NDC 0032-1206-01)
250 capsules (NDC 0032-1206-07)
Pancreatin (Wobenzym N Tablets) (pancrelipase) Delayed-Release Capsules12,000 USP units of lipase; 38,000 USP units of protease; 60,000 USP units of amylase
Each Pancreatin (Wobenzym N Tablets) capsule is available as a two-piece gelatin capsule with a brown opaque cap with imprint “Pancreatin (Wobenzym N Tablets) 1212” and a colorless transparent body that contains tan-colored, delayed-release pancrelipase supplied in bottles of:
100 capsules (NDC 0032-1212-01)
250 capsules (NDC 0032-1212-07)
Pancreatin (Wobenzym N Tablets) (pancrelipase) Delayed-Release Capsules24,000 USP units of lipase; 76,000 USP units of protease; 120,000 USP units of amylase
Each Pancreatin (Wobenzym N Tablets) capsule is available as a two-piece gelatin capsule with orange opaque cap with imprint “Pancreatin (Wobenzym N Tablets) 1224” and a colorless transparent body that contains tan-colored, delayed-release pancrelipase supplied in bottles of:
100 capsules (NDC 0032-1224-01)
250 capsules (NDC 0032-1224-07)
Pancreatin (Wobenzym N Tablets) (pancrelipase) Delayed-Release Capsules36,000 USP units of lipase; 114,000 USP units of protease; 180,000 USP units of amylase
Each Pancreatin (Wobenzym N Tablets) capsule is available as a two-piece gelatin capsule with blue opaque cap with imprint “Pancreatin (Wobenzym N Tablets) 1236” and a colorless transparent body that contains tan-colored, delayed-release pancrelipase supplied in bottles of:
100 capsules (NDC 0032-3016-13)
250 capsules (NDC 0032-3016-28)
Storage and HandlingPancreatin (Wobenzym N Tablets) must be stored at room temperature up to 25°C (77°F) and protected from moisture. Temperature excursions are permitted between 25°C to 40°C (77°F and 104°F) for up to 30 days. Product should be discarded if exposed to higher temperature and moisture conditions higher than 70%. After opening, keep bottle tightly closed between uses to protect from moisture.
Bottles of Pancreatin (Wobenzym N Tablets) 3,000 USP units of lipase must be stored and dispensed in the original container.
Do not crush Pancreatin (Wobenzym N Tablets) delayed-release capsules or the capsule contents.
REFERENCES
1 Borowitz DS, Grand RJ, Durie PR, et al. Use of pancreatic enzyme supplements for patients with cystic fibrosis in the context of fibrosing colonopathy. Journal of Pediatrics. 1995; 127: 681-684.
2 Borowitz DS, Baker RD, Stallings V. Consensus report on nutrition for pediatric patients with cystic fibrosis. Journal of Pediatric Gastroenterology Nutrition. 2002 Sep; 35: 246-259.
3 Stallings VA, Stark LJ, Robinson KA, et al. Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. Journal of the American Dietetic Association. 2008; 108: 832-839.
4 Dominguez-Munoz JE. Pancreatic enzyme therapy for pancreatic exocrine insufficiency. Current Gastroenterology Reports. 2007; 9: 116-122.
Manufactured by: Abbott Laboratories GmbH, Hannover, Germany. Marketed by: AbbVie Inc., North Chicago, IL 60064, U.S.A. Revised: September, 2012
Chew or suck 2 tab qds for the 1st day, then 1 tab qds for at least 5 days.
There is no evidence of incompatibility of Bromelains (Wobenzym N Tablets)® with other simultaneously administered drugs. Nevertheless, in case of taking other prescription medicines or OTC drugs consult Bromelains (Wobenzym N Tablets)® administration with your physician and do not take it without his recommendation. If your physician prescribes you another medicine, inform him that you use Bromelains (Wobenzym N Tablets)®.
See also:
What other drugs will affect Pancreatin (Wobenzym N Tablets)?
Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.
Some products that may interact with this drug include: acarbose, miglitol.
Anti-coagulants.
